Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STATION-FIRST study of midazolam pharmacokinetics and pharmacodynamics in continuous palliative sedation
NL-OMON58126Recruiting
- Sponsor
- Erasmus MC
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of midazolam in Refractory symptoms in terminal illness, sponsored by Erasmus MC. Primary endpoints: Pharmacodynamic covariates affecting midazolam in continuous palliative sedation and Clinical pharmacodynamic parameter estimation. Started Feb 2026; status: recruiting.
02
Drugs
midazolam
03
Conditions
Refractory symptoms in terminal illness
Beyond the preview
Go deeper on NL-OMON58126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58126.